|

|
Conferences & Courses
|
Integrated Drug Safety Risk Assessments
June 4-6, 2013 | Philadelphia, PA
Predictive Drug Safety highlights innovative preclinical strategies that are underway, for predicting drug-induced organ toxicities early and accurately.
|
|
Targeting Histone Methyltransferases
September 24-25, 2013 | Boston, MA
Building on the success of last year, Cambridge Healthtech Institute's Second Annual Targeting Histone Methyltransferases conference, September 24-25 in Boston, is the preeminent event for HMTi development, gathering a diverse cross-section of academi
|
|
|
|
|
|
|
Life Science Media Library
|
Characterization and Analysis of Visible &Sub-Visible Particulates DVD
January 8, 2012 |
Sub-visible particles present in these biopharmaceutical products are a product quality attribute and a potential patient safety concerns yet to be fully explored. Early and consistent particle detection, quantitation and control throughout the product life cycle of these drugs from development to commercial lot release is critical in mitigating any concerns. This requires appropriate analytical methods which can be applied to biopharmaceuticals across a large variety of protein concentrations and modes of administration. This DVD will cover strategies to utilize complementary methods and techniques at different phases of product development.
|
Immunogenicity Prediction and Mitigation DVD
November 18, 2011 |
Escherichia coli has proven its worth as a protein expression platform. Currently, E.coli is not viewed so much as an ‘alternative’ platform, but as a viable choice for achieving high-level expression of human genes and proteins at a reasonable cost.
|
Immunogenicity Assessment and Clinical Relevance DVD
November 16, 2011 |
Escherichia coli has proven its worth as a protein expression platform. Currently, E.coli is not viewed so much as an ‘alternative’ platform, but as a viable choice for achieving high-level expression of human genes and proteins at a reasonable cost.
|
|
|
|
Publications, Reports, & Whitepapers
|
|
|
Cardiotoxicity: Issues, Technologies, and Solutions for the Future
This report identifies and discusses methods, products, and services that are designed to identify cardiotoxic compounds before they reach the market, discusses the current and possible future regulatory environment, outlines main commercial competitors, and suggests broad types of commercial opportunity and future M&A activity in this subsector. Although the primary focus is on identification of proarrhythmia, identification of other forms of cardiotoxicity is also discussed.
|
|
|
|
|
|
|